← 產業報告目錄

US and Europe Pharma and Biotech Cro Market Research Report by Service Type (Clinical Development Services, Formulation Development Services, Pharmacovigilance Services, Laboratory Services, Consulting Services, Data Management Services, and Others), by Phase {Based on phase, the US and Europe Pharma and Biotech CRO Market has been segmented into Phase I, Phase II, Phase III, Phase IV. and Post Marketing Studies (PMS)}, by Indication 9 Based on Indication, the US and Europe Pharma and Biotech CRO Market has been segmented into cardiovascular, oncology, dermatology, gynecology, neurology, respiratory diseases, orthopedics, ophthalmology and others), by End User (Pharmaceutical Companies, and Biopharmaceutical Companies) Forecast to 2032

出版商 Market Research Future產業別 Healthcare & Life Sciences出版日期 2025-01-03頁數 198報告編號 MRFRHC300053CR

授權報價

Single User Price$2,950 USD
Multi User Licence (up to 10 users)$3,950 USD
Enterprisewide Price (Global Site License)$5,250 USD
洽詢購買 申請 Sample

報告摘要

US and Europe Pharma and Biotech Cro Market Research Report by Service Type (Clinical Development Services, Formulation Development Services, Pharmacovigilance Services, Laboratory Services, Consulting Services, Data Management Services, and Others), by Phase {Based on phase, the US and Europe Pharma and Biotech CRO Market has been segmented into Phase I, Phase II, Phase III, Phase IV. and Post Marketing Studies (PMS)}, by Indication 9 Based on Indication, the US and Europe Pharma and Biotech CRO Market has been segmented into cardiovascular, oncology, dermatology, gynecology, neurology, respiratory diseases, orthopedics, ophthalmology and others), by End User (Pharmaceutical Companies, and Biopharmaceutical Companies) Forecast to 2032 Market Overview US and Europe Pharma and Biotech Cro Market is anticipated to register a healthy market expansion at a CAGR of 10.32% during the review period. CROs (Contract Research Organizations) play an important role in the pharmaceutical and biotechnology industries by providing outsourced services such as drug development, clinical trials, regulatory affairs, and more. These include drug development, clinical trials, regulatory affairs, and post-market surveillance. CROs help streamline the drug development process by managing various aspects of clinical trials, from design and protocol development to patient recruitment, data collection, and analysis. The increasing research and development investments by pharmaceutical and biotechnology industries, adoption of cutting-edge technology such as artificial intelligence, big data analytics, and precision medicine, and increased number of clinical trials and studies generates demand for CRO services for trial management and support are the major factors driving the growth of the US & Europe pharma and biotech CRO market. However, the intense competition among CROs and data privacy and security concerns are expected to hamper the growth of the global market. Nevertheless, emerging markets offer significant growth opportunities, and the growing investment in personalized and precision medicine is anticipated to create lucrative opportunities for the market. Market Segmentation Based on Service Type, the US and Europe Pharma and Biotech CRO Market has been segmented into clinical development services, formulation development services, pharmacovigilance services, laboratory services, consulting services, data management services, and others includes regulatory affairs services and others. Based on phase, the Market has been segmented into Phase I, Phase II, Phase III, Phase IV. and Post Marketing Studies (PMS). Based on Indication, the Market has been segmented into cardiovascular, oncology, dermatology, gynecology, neurology, respiratory diseases, orthopedics, ophthalmology and others includes. Based on end user, the US and Europe Pharma and Biotech CRO Market has been segmented into pharmaceutical companies, and biopharmaceutical companies. Based on region/country, the Market has been segmented into US, and Europe. Major Players The key market players include KLIF, Ergomed Group, Astrum CRO, Ergomed Group, Optimapharm, FGK Clinical Research, Kapadi, TFS HealthScience, Winicker Norimed GmbH, JSB Solutions Srl, and IQVIA Holding, Inc.
目錄 Table of Contents
TABLE OF CONTENTS 1 EXECUTIVE SUMMARY 19 2 MARKET INTRODUCTION 21 2.1 DEFINITION 21 2.2 SCOPE OF THE STUDY 21 2.3 RESEARCH OBJECTIVE 21 2.4 MARKET STRUCTURE 21 3 RESEARCH METHODOLOGY 22 3.1 OVERVIEW 22 3.2 DATA FLOW 24 3.2.1 DATA MINING PROCESS 24 3.3 PURCHASED DATABASE: 25 3.4 SECONDARY SOURCES: 26 3.4.1 SECONDARY RESEARCH DATA FLOW: 27 3.5 PRIMARY RESEARCH: 28 3.5.1 PRIMARY RESEARCH DATA FLOW: 29 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED 30 3.6 APPROACHES FOR MARKET SIZE ESTIMATION: 31 3.6.1 REVENUE ANALYSIS APPROACH 31 3.7 DATA FORECASTING 32 3.7.1 DATA FORECASTING TYPE 32 3.8 DATA MODELING 33 3.8.1 MICROECONOMIC FACTOR ANALYSIS: 33 3.8.2 DATA MODELING: 34 3.9 TEAMS AND ANALYST CONTRIBUTION 36 4 MARKET DYNAMICS 38 4.1 INTRODUCTION 38 4.2 DRIVERS 39 4.2.1 INCREASING RESEARCH AND DEVELOPMENT INVESTMENTS BY PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES 39 4.2.2 GROWING ADOPTION OF CUTTING-EDGE TECHNOLOGY SUCH AS ARTIFICIAL INTELLIGENCE, BIG DATA ANALYTICS, AND PRECISION MEDICINE 39 4.2.3 INCREASED NUMBER OF CLINICAL TRIALS AND STUDIES GENERATES DEMAND FOR CRO SERVICES FOR TRIAL MANAGEMENT AND SUPPORT 40 4.3 RESTRAINTS 41 4.3.1 HIGH COST OF PHOTODYNAMIC THERAPY EQUIPMENT AND PROCEDURES 41 4.4 OPPORTUNITY 42 4.4.1 GROWING INVESTMENT IN PERSONALIZED AND PRECISION MEDICINE 42 5 MARKET FACTOR ANALYSIS 44 5.1 PORTER'S FIVE FORCES MODEL 44 5.1.1 THREAT OF NEW ENTRANTS 44 5.1.2 BARGAINING POWER OF SUPPLIERS 45 5.1.3 THREAT OF SUBSTITUTES 45 5.1.4 BARGAINING POWER OF BUYERS 45 5.1.5 INTENSITY OF RIVALRY 45 5.2 IMPACT OF COVID-19 ON THE US & EUROPE PHARMA AND BIOTECH CRO MARKET 46 5.3 LIST OF CONTRACT RESEARCH ORGANIZATION BY EUROPE/EUROPE COUNTRIES OFFERING SERVICES TO PHARMACEUTICAL AND BIOPHARMACEUTICAL 47 6 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE 53 6.1 OVERVIEW 53 6.2 CLINICAL DEVELOPMENT SERVICES 56 6.3 FORMULATION DEVELOPMENT SERVICES 56 6.4 PHARMACOVIGILANCE SERVICES 56 6.5 LABORATORY SERVICES 57 6.6 CONSULTING SERVICES 57 6.7 DATA MANAGEMENT SERVICES 58 6.8 OTHERS 58 7 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, BY PHASE 59 7.1 OVERVIEW 59 7.2 PHASE I 62 7.3 PHASE II 62 7.4 PHASE III 62 7.5 PHASE IV 63 7.6 POST MARKETING STUDIES (PMS) 63 8 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, BY INDICATION 64 8.1 OVERVIEW 64 8.2 CARDIOVASCULAR 67 8.3 ONCOLOGY 67 8.4 DERMATOLOGY 67 8.5 GYNAECOLOGY 68 8.6 NEUROLOGY 68 8.7 RESPIRATORY DISEASES 68 8.8 ORTHOPAEDICS 69 8.9 OPHTHALMOLOGY 69 8.10 OTHERS 69 9 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, BY END USER 70 9.1 OVERVIEW 70 9.2 PHARMACEUTICAL COMPANIES 72 9.3 BIOPHARMACEUTICAL COMPANIES 72 10 US & EUROPE PHARMA AND BIOTECH CRO MARKET, BY REGION 73 10.1 OVERVIEW 73 10.2 US 75 10.3 EUROPE 78 10.4 EASTERN EUROPE 82 10.4.1 POLAND 86 10.4.2 ROMANIA 88 10.4.3 BULGARIA 90 10.4.4 BELARUS 92 10.4.5 GEORGIA 94 10.4.6 LATVIA 96 10.4.7 LITHUANIA 98 10.4.8 REST OF EASTERN EUROPE 100 10.5 WESTERN EUROPE 102 10.5.1 GERMANY 105 10.5.2 FRANCE 107 10.5.3 UK 109 10.5.4 SPAIN 111 10.5.5 SWITZERLAND 113 10.5.6 NETHERLANDS 115 10.5.7 REST OF WESTERN EUROPE 117 10.6 NORTHERN EUROPE 120 10.6.1 DENMARK 123 10.6.2 SWEDEN 125 10.6.3 NORWAY 127 10.6.4 ICELAND 129 10.6.5 FINLAND 131 10.6.6 IRELAND 133 10.6.7 REST OF NORTHERN EUROPE 135 10.7 SOUTHERN EUROPE 138 10.7.1 GREECE 141 10.7.2 PORTUGAL 143 10.7.3 CROATIA 145 10.7.4 REST OF SOUTHERN EUROPE 147 10.8 CENTRAL EUROPE 149 10.8.1 HUNGARY 153 10.8.2 SLOVAKIA 155 10.8.3 CZECH REPUBLIC 157 10.8.4 AUSTRIA 159 10.8.5 REST OF CENTRAL EUROPE 161 11 COMPETITIVE LANDSCAPE 164 11.1 INTRODUCTION 164 11.2 MARKET SHARE ANALYSIS, 2023 164 11.3 COMPETITOR DASHBOARD 165 11.4 PUBLIC PLAYERS STOCK SUMMARY 166 11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL 166 11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 166 11.6.1 AQUISITION 166 11.6.2 FACILITY LAUNCH 168 11.6.3 INVESTMENT 168 11.6.4 EXPANSION 168 12 COMPANY PROFILES 169 12.1 KLIFO 169 12.1.1 COMPANY OVERVIEW 169 12.1.2 FINANCIAL OVERVIEW 169 12.1.3 SERVICE OFFERED 170 12.1.4 KEY DEVELOPMENTS 171 12.1.5 KEY STRATEGIES 171 12.2 OPTIMAPHARM 172 12.2.1 COMPANY OVERVIEW 172 12.2.2 FINANCIAL OVERVIEW 172 12.2.3 SERVICES OFFERED 173 12.2.4 KEY DEVELOPMENTS 174 12.2.5 SWOT ANALYSIS 175 12.2.6 KEY STRATEGIES 175 12.3 FGK CLINICAL RESEARCH GMBH 176 12.3.1 COMPANY OVERVIEW 176 12.3.2 FINANCIAL OVERVIEW 176 12.3.3 SERVICE OFFERED 177 12.3.4 KEY DEVELOPMENTS 178 12.3.5 KEY STRATEGIES 178 12.4 ERGOMED GROUP 179 12.4.1 COMPANY OVERVIEW 179 12.4.2 FINANCIAL OVERVIEW 180 12.4.3 SERVICE OFFERED 180 12.4.4 KEY DEVELOPMENTS 181 12.4.5 SWOT ANALYSIS 182 12.4.6 KEY STRATEGIES 182 12.5 ASTRUM/ PHARMALOG 183 12.5.1 COMPANY OVERVIEW 183 12.5.2 FINANCIAL OVERVIEW 183 12.5.3 SERVICE OFFERED 184 12.5.4 KEY DEVELOPMENTS 184 12.5.5 KEY STRATEGIES 184 12.6 KAPADI 185 12.6.1 COMPANY OVERVIEW 185 12.6.2 FINANCIAL OVERVIEW 186 12.6.3 SERVICES OFFERED 186 12.6.4 KEY DEVELOPMENTS 186 12.6.5 SWOT ANALYSIS 187 12.6.6 KEY STRATEGIES 187 12.7 TFS HEALTHSCIENCE 188 12.7.1 COMPANY OVERVIEW 188 12.7.2 FINANCIAL OVERVIEW 188 12.7.3 SERVICES OFFERED 189 12.7.4 KEY DEVELOPMENTS 189 12.7.5 KEY STRATEGIES 189 12.8 WINICKER NORIMED GMBH 190 12.8.1 COMPANY OVERVIEW 190 12.8.2 FINANCIAL OVERVIEW 190 12.8.3 SERVICES OFFERED 190 12.8.4 KEY DEVELOPMENTS 191 12.8.5 SWOT ANALYSIS 191 12.8.6 KEY STRATEGIES 191 12.9 JSB SOLUTIONS SRL 192 12.9.1 COMPANY OVERVIEW 192 12.9.2 FINANCIAL OVERVIEW 192 12.9.3 SERVICES OFFERED 193 12.9.4 KEY DEVELOPMENTS 193 12.9.5 KEY STRATEGIES 193 12.10 IQVIA HOLDING, INC 194 12.10.1 COMPANY OVERVIEW 194 12.10.2 FINANCIAL OVERVIEW 195 12.10.3 SERVICES OFFERED 195 12.10.4 KEY DEVELOPMENTS 196 12.10.5 SWOT ANALYSIS 196 12.10.6 KEY STRATEGIES 196 13 DATA CITATIONS 197
圖表清單 List of Tables & Figures
LIST OF TABLES TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 34 TABLE 2 LIST OF CONTRACT RESEARCH ORGANIZATION BY EUROPE/EUROPE COUNTRIES OFFERING SERVICES TO PHARMACEUTICAL AND BIOPHARMACEUTICAL 47 TABLE 3 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 54 TABLE 4 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR CLINICAL DEVELOPMENT SERVICES, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 56 TABLE 5 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR FORMULATION DEVELOPMENT SERVICES, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 56 TABLE 6 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR PHARMACOVIGILANCE SERVICES, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 56 TABLE 7 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR LABORATORY SERVICES, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 57 TABLE 8 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR CONSULTING SERVICES, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 57 TABLE 9 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR DATA MANAGEMENT SERVICES, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 58 TABLE 10 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR OTHERS, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 58 TABLE 11 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 60 TABLE 12 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR PHASE I, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 62 TABLE 13 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR PHASE II, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 62 TABLE 14 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR PHASE III, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 62 TABLE 15 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR PHASE IV, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 63 TABLE 16 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR POST MARKETING STUDIES (PMS), BY COUNTRY/REGION, 2019–2032 (USD MILLION) 63 TABLE 17 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 65 TABLE 18 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR CARDIOVASCULAR, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 67 TABLE 19 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR ONCOLOGY, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 67 TABLE 20 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR DERMATOLOGY, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 67 TABLE 21 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR GYNAECOLOGY, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 68 TABLE 22 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR NEUROLOGY, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 68 TABLE 23 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR RESPIRATORY DISEASES, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 68 TABLE 24 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR ORTHOPAEDICS, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 69 TABLE 25 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR OPHTHALMOLOGY, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 69 TABLE 26 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR OTHERS, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 69 TABLE 27 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 71 TABLE 28 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR PHARMACEUTICAL COMPANIES, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 72 TABLE 29 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, FOR BIOPHARMACEUTICAL COMPANIES, BY COUNTRY/REGION, 2019–2032 (USD MILLION) 72 TABLE 30 US & EUROPE PHARMA AND BIOTECH CRO MARKET, BY REGION, 2019–2032 (USD MILLION) 73 TABLE 31 US: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 76 TABLE 32 US: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD BILLION) 76 TABLE 33 US: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 77 TABLE 34 US: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 77 TABLE 35 EUROPE: PHARMA AND BIOTECH CRO MARKET, BY REGION, 2019–2032 (USD MILLION) 79 TABLE 36 EUROPE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 80 TABLE 37 EUROPE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD BILLION) 81 TABLE 38 EUROPE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 81 TABLE 39 EUROPE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 82 TABLE 40 EASTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY REGION, 2019–2032 (USD MILLION) 83 TABLE 41 EASTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 84 TABLE 42 EASTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD BILLION) 84 TABLE 43 EASTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 85 TABLE 44 EASTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 85 TABLE 45 POLAND: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 86 TABLE 46 POLAND: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD BILLION) 86 TABLE 47 POLAND: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 87 TABLE 48 POLAND: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 87 TABLE 49 ROMANIA: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 88 TABLE 50 ROMANIA: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD BILLION) 88 TABLE 51 ROMANIA: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 89 TABLE 52 ROMANIA: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 89 TABLE 53 BULGARIA: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 90 TABLE 54 BULGARIA: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD BILLION) 90 TABLE 55 BULGARIA: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 91 TABLE 56 BULGARIA: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 91 TABLE 57 BELARUS: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 92 TABLE 58 BELARUS: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD BILLION) 92 TABLE 59 BELARUS: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 93 TABLE 60 BELARUS: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 93 TABLE 61 GEORGIA: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 94 TABLE 62 GEORGIA: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD BILLION) 94 TABLE 63 GEORGIA: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 95 TABLE 64 GEORGIA: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 95 TABLE 65 LATVIA: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 96 TABLE 66 LATVIA: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD BILLION) 96 TABLE 67 LATVIA: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 97 TABLE 68 LATVIA: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 97 TABLE 69 LITHUANIA: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 98 TABLE 70 LITHUANIA: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD BILLION) 98 TABLE 71 LITHUANIA: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 99 TABLE 72 LITHUANIA: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 99 TABLE 73 REST OF EASTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 100 TABLE 74 REST OF EASTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD BILLION) 100 TABLE 75 REST OF EASTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 101 TABLE 76 REST OF EASTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 101 TABLE 77 WESTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY COUNTRY, 2019–2032 (USD MILLION) 102 TABLE 78 WESTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 103 TABLE 79 WESTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 104 TABLE 80 WESTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 104 TABLE 81 WESTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 105 TABLE 82 GERMANY: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 105 TABLE 83 GERMANY: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 106 TABLE 84 GERMANY: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 106 TABLE 85 GERMANY: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 107 TABLE 86 FRANCE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 107 TABLE 87 FRANCE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 108 TABLE 88 FRANCE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 108 TABLE 89 FRANCE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 109 TABLE 90 UK: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 109 TABLE 91 UK: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 110 TABLE 92 UK: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 110 TABLE 93 UK: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 111 TABLE 94 SPAIN: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 111 TABLE 95 SPAIN: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 112 TABLE 96 SPAIN: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 112 TABLE 97 SPAIN: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 113 TABLE 98 SWITZERLAND: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 113 TABLE 99 SWITZERLAND: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 114 TABLE 100 SWITZERLAND: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 114 TABLE 101 SWITZERLAND: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 115 TABLE 102 NETHERLANDS: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 115 TABLE 103 NETHERLANDS: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 116 TABLE 104 NETHERLANDS: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 116 TABLE 105 NETHERLANDS: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 117 TABLE 106 REST OF WESTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 117 TABLE 107 REST OF WESTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 118 TABLE 108 REST OF WESTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 118 TABLE 109 REST OF WESTERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 119 TABLE 110 NORTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY COUNTRY, 2019–2032 (USD MILLION) 120 TABLE 111 NORTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 121 TABLE 112 NORTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 122 TABLE 113 NORTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 122 TABLE 114 NORTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 123 TABLE 115 DENMARK: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 123 TABLE 116 DENMARK: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 124 TABLE 117 DENMARK: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 124 TABLE 118 DENMARK: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 125 TABLE 119 SWEDEN: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 125 TABLE 120 SWEDEN: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 126 TABLE 121 SWEDEN: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 126 TABLE 122 SWEDEN: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 127 TABLE 123 NORWAY: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 127 TABLE 124 NORWAY: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 128 TABLE 125 NORWAY: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 128 TABLE 126 NORWAY: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 129 TABLE 127 ICELAND: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 129 TABLE 128 ICELAND: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 130 TABLE 129 ICELAND: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 130 TABLE 130 ICELAND: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 131 TABLE 131 FINLAND: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 131 TABLE 132 FINLAND: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 132 TABLE 133 FINLAND: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 132 TABLE 134 FINLAND: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 133 TABLE 135 IRELAND: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 133 TABLE 136 IRELAND: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 134 TABLE 137 IRELAND: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 134 TABLE 138 IRELAND: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 135 TABLE 139 REST OF NORTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 135 TABLE 140 REST OF NORTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 136 TABLE 141 REST OF NORTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 136 TABLE 142 REST OF NORTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 137 TABLE 143 SOUTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY COUNTRY, 2019–2032 (USD MILLION) 138 TABLE 144 SOUTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 139 TABLE 145 SOUTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 140 TABLE 146 SOUTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 140 TABLE 147 SOUTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 141 TABLE 148 GREECE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 141 TABLE 149 GREECE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 142 TABLE 150 GREECE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 142 TABLE 151 GREECE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 143 TABLE 152 PORTUGAL: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 143 TABLE 153 PORTUGAL: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 144 TABLE 154 PORTUGAL: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 144 TABLE 155 PORTUGAL: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 145 TABLE 156 CROATIA: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 145 TABLE 157 CROATIA: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 146 TABLE 158 CROATIA: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 146 TABLE 159 CROATIA: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 147 TABLE 160 REST OF SOUTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 147 TABLE 161 REST OF SOUTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 148 TABLE 162 REST OF SOUTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 148 TABLE 163 REST OF SOUTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 149 TABLE 164 CENTRAL EUROPE: PHARMA AND BIOTECH CRO MARKET, BY COUNTRY, 2019–2032 (USD MILLION) 150 TABLE 165 CENTRAL EUROPE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 151 TABLE 166 CENTRAL EUROPE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 151 TABLE 167 CENTRAL EUROPE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 152 TABLE 168 CENTRAL EUROPE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 152 TABLE 169 HUNGARY: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 153 TABLE 170 HUNGARY: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 153 TABLE 171 HUNGARY: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 154 TABLE 172 HUNGARY: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 154 TABLE 173 SLOVAKIA: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 155 TABLE 174 SLOVAKIA: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 155 TABLE 175 SLOVAKIA: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 156 TABLE 176 SLOVAKIA: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 156 TABLE 177 CZECH REPUBLIC: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 157 TABLE 178 CZECH REPUBLIC: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 157 TABLE 179 CZECH REPUBLIC: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 158 TABLE 180 CZECH REPUBLIC: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 158 TABLE 181 AUSTRIA: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 159 TABLE 182 AUSTRIA: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 159 TABLE 183 AUSTRIA: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 160 TABLE 184 AUSTRIA: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 160 TABLE 185 REST OF CENTRAL EUROPE: PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 161 TABLE 186 REST OF CENTRAL EUROPE: PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2019–2032 (USD MILLION) 161 TABLE 187 REST OF CENTRAL EUROPE: PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2019–2032 (USD MILLION) 162 TABLE 188 REST OF CENTRAL EUROPE: PHARMA AND BIOTECH CRO MARKET, BY END USER, 2019–2032 (USD MILLION) 162 TABLE 189 AQUISITION 166 TABLE 190 FACILITY LAUNCH 168 TABLE 191 INVESTMENT 168 TABLE 192 EXPANSION 168 TABLE 193 KLIFO: SERVICES OFFERED 170 TABLE 194 KLIFO: KEY DEVELOPMENTS 171 TABLE 195 OPTIMAPHARM: SERVICES OFFERED 173 TABLE 196 OPTIMAPHARM: KEY DEVELOPMENTS 174 TABLE 197 FGK CLINICAL RESEARCH: SERVICES OFFERED 177 TABLE 198 FGK CLINICAL RESEARCH: KEY DEVELOPMENTS 178 TABLE 199 ERGOMED GROUP: SERVICES OFFERED 180 TABLE 200 ERGOMED GROUP: KEY DEVELOPMENTS 181 TABLE 201 ASTRUM/PHARMLOG: SERVICES OFFERED 184 TABLE 202 ASTRUM/PHARMLOG: SERVICES OFFERED 184 TABLE 203 KAPADI: SERVICES OFFERED 186 TABLE 204 TFS HEALTHSCIENCE: SERVICES OFFERED 189 TABLE 205 WINICKER NORIMED GMBH: SERVICES OFFERED 190 TABLE 206 JSB SOLUTIONS SRL: SERVICE OFFERED 193 TABLE 207 IQVIA HOLDING, INC: SERVICES OFFERED 195 LIST OF FIGURES FIGURE 1 US AND EUROPE PHARMA AND BIOTECH CRO MARKET: STRUCTURE 21 FIGURE 2 US & EUROPE PHARMA AND BIOTECH CRO MARKET: MARKET GROWTH FACTOR ANALYSIS (2023-2032) 38 FIGURE 3 DRIVER IMPACT ANALYSIS (2019-2032) 40 FIGURE 4 RESTRAINT IMPACT ANALYSIS (2029-2032) 42 FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: US & EUROPE PHARMA AND BIOTECH CRO MARKET 44 FIGURE 6 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, SERVICE TYPE, 2023 & 2032 (USD MILLION) 53 FIGURE 7 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, BY SERVICE TYPE, 2023 & 2032 (USD MILLION) 54 FIGURE 8 US AND EUROPE PHARMA AND BIOTECH CRO MARKET SHARE (%), BY SERVICE TYPE, 2023 55 FIGURE 9 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, PHASE, 2023 & 2032 (USD MILLION) 59 FIGURE 10 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, BY PHASE, 2023 & 2032 (USD MILLION) 60 FIGURE 11 US AND EUROPE PHARMA AND BIOTECH CRO MARKET SHARE (%), BY PHASE, 2023 61 FIGURE 12 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, INDICATION, 2023 & 2032 (USD MILLION) 64 FIGURE 13 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, BY INDICATION, 2023 & 2032 (USD MILLION) 65 FIGURE 14 US AND EUROPE PHARMA AND BIOTECH CRO MARKET SHARE (%), BY INDICATION, 2023 66 FIGURE 15 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, END USER, 2023 & 2032 (USD MILLION) 70 FIGURE 16 US AND EUROPE PHARMA AND BIOTECH CRO MARKET, BY END USER, 2023 & 2032 (USD MILLION) 71 FIGURE 17 US AND EUROPE PHARMA AND BIOTECH CRO MARKET SHARE (%), BY END USER, 2023 71 FIGURE 18 US & EUROPE PHARMA AND BIOTECH CRO MARKET, BY REGION, 2023 & 2032 (USD MILLION) 73 FIGURE 19 US & EUROPE PHARMA AND BIOTECH CRO MARKET SHARE, BY REGION, 2023 (% SHARE) 74 FIGURE 20 US MARKET ANALYSIS: PHARMA AND BIOTECH CRO MARKET, 2019-2032 (USD MILLION) 75 FIGURE 21 EUROPE MARKET ANALYSIS: PHARMA AND BIOTECH CRO MARKET, 2019-2032 (USD MILLION) 78 FIGURE 22 EUROPE PHARMA AND BIOTECH CRO MARKET SHARE, BY REGION, 2023 & 2032 (USD MILLION) 79 FIGURE 23 EUROPE PHARMA AND BIOTECH CRO MARKET SHARE, BY REGION, 2023 (%) 80 FIGURE 24 EASTERN EUROPE PHARMA AND BIOTECH CRO MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION) 82 FIGURE 25 EASTERN EUROPE PHARMA AND BIOTECH CRO MARKET SHARE, BY REGION, 2023 (%) 83 FIGURE 26 WESTERN EUROPE: PHARMA AND BIOTECH CRO MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION) 102 FIGURE 27 WESTERN EUROPE: PHARMA AND BIOTECH CRO MARKET SHARE, BY COUNTRY, 2023 (%) 103 FIGURE 28 NORTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION) 120 FIGURE 29 NORTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET SHARE, BY COUNTRY, 2023 (%) 121 FIGURE 30 SOUTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION) 138 FIGURE 31 SOUTHERN EUROPE: PHARMA AND BIOTECH CRO MARKET SHARE, BY COUNTRY, 2023 (%) 139 FIGURE 32 CENTRAL EUROPE: PHARMA AND BIOTECH CRO MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION) 149 FIGURE 33 CENTRAL EUROPE: PHARMA AND BIOTECH CRO MARKET SHARE, BY COUNTRY, 2023 (%) 150 FIGURE 34 US AND EUROPE PHARMA AND BIOTECH CRO MARKET PLAYERS: COMPETITIVE ANALYSIS, 2023 164 FIGURE 35 COMPETITOR DASHBOARD: US AND EUROPE PHARMA AND BIOTECH CRO MARKET 165 FIGURE 36 OPTIMAPHARM: SWOT ANALYSIS 175 FIGURE 37 ERGOMED GROUP: SWOT ANALYSIS 182 FIGURE 38 KAPADI: SWOT ANALYSIS 187 FIGURE 39 WINICKER NORIMED GMBH: SWOT ANALYSIS 191 FIGURE 40 IQVIA HOLDING, INC: SWOT ANALYSIS 195 FIGURE 41 IQVIA HOLDING, INC: SWOT ANALYSIS 196

提及公司

KLIFErgomed GroupAstrum CROErgomed GroupOptimapharmFGK Clinical ResearchKapadiTFS HealthScienceWinicker Norimed GmbHJSB Solutions Srland IQVIA HoldingInc.

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們